Resolution Therapeutics has signed agreements to access lipid nanoparticle (LNP) technology to develop its in vivo Regenerative Macrophage Therapy (RMT) for inflammatory and fibrotic diseases. This new program aims to complement its ongoing autologous therapy RTX001, currently in Phase 1/2 trials for end-stage liver disease, by enabling broader patient access through optimized mRNA delivery. The company expects preliminary results later this year and aims to identify an efficient LNP delivery system to accelerate therapy development. This dual approach could expand treatment options for patients with chronic inflammatory and fibrotic conditions beyond liver disease.
Innovator Capital Management announced the liquidation of two ETFs: the Innovator Gradient Tactical Rotation Strategy ETF and the Innovator Hedged Nasdaq-100 ETF. Trading for these funds will cease after market close on July 10, 2026, with liquidatio...
AlphaPepe has confirmed its first centralized exchange partnership with Azbit as part of its launch preparations, raising $1.65 million in its presale with over 8,600 holders. The project is also developing its AlphaSwap platform and has completed a ...
Monteverde & Associates PC, a top class action law firm, is investigating mergers involving Pacific Financial Corporation (PFLC), Nuvalent, Inc. (NUVL), Cross Country Healthcare, Inc. (CCRN), and Bio Green Med Solution, Inc. (BGMS). Shareholders of t...
Hi*Ball Energy, a sparkling energy drink made with natural caffeine, vitamins, guarana, and ginseng, has officially launched in the UK. The drink contains no sugar, calories, or artificial sweeteners and targets health-conscious consumers seeking a r...
Hi*Ball Energy, a sparkling energy water brand by Tilray Brands, has officially launched in the UK, available via Amazon UK and BrewDog.com. The drink contains natural caffeine, B vitamins, guarana, and ginseng, providing a sugar-free, calorie-free e...
